Patrys Ltd
ASX:PAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Patrys Ltd
ASX:PAB
|
AU |
|
A
|
Allied Copper Corp
XTSX:CPR
|
CA |
|
Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
|
CN |
|
Huapont Life Sciences Co Ltd
SZSE:002004
|
CN |
|
Y
|
YIT Oyj
OMXH:YIT
|
FI |
|
Amergent Hospitality Group Inc
OTC:AMHG
|
US |
|
W
|
Whirlpool SA
BOVESPA:WHRL3
|
BR |
|
China Aluminum Cans Holdings Ltd
HKEX:6898
|
CN |
|
Strawbear Entertainment Group
HKEX:2125
|
CN |
|
EGL Holdings Co Ltd
HKEX:6882
|
HK |
|
T
|
Tempus Holdings Ltd
HKEX:6880
|
HK |
|
Overseas Education Ltd
SGX:RQ1
|
SG |
|
KTK GROUP Co Ltd
SSE:603680
|
CN |
Patrys Ltd
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
